These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1535212)

  • 21. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The cardiac toxicity of cancer chemotherapy].
    Sequeira JF; Madruga IM; Ribeiro M; Duarte PC; Ferreira DC; Sarmento JL
    Acta Med Port; 1994 May; 7(5):311-8. PubMed ID: 8073908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
    Lopez M
    Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Serial determination of anthracycline poisoning in children].
    Stein JI; Langevin A; Benson LN; Souza MD; Wilson G; Chan H
    Wien Klin Wochenschr; 1989 Jan; 101(1):45-8. PubMed ID: 2913725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
    Theodoulou M; Hudis C
    Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endomyocardial biopsy.
    Schneiderman H; Hager WD; Gondos B
    Ann Clin Lab Sci; 1986; 16(2):134-45. PubMed ID: 3516054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
    Appel JM; Rybjerg M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
    [No Abstract]   [Full Text] [Related]  

  • 35. [Diagnostic possibilities of late cardiotoxic sequelae of chemotherapy with anthracyclines].
    Elbl L; Hrstková H; Chaloupka V; Novotný J
    Vnitr Lek; 2002 Oct; 48(10):981-8. PubMed ID: 16737150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endomyocardial biopsy.
    Laser JA; Fowles RE; Mason JW
    Cardiovasc Clin; 1985; 15(1):141-63. PubMed ID: 3916087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
    Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
    Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthracycline cardiotoxicity: one size does not fit all!
    Hershman DL; Neugut AI
    J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
    [No Abstract]   [Full Text] [Related]  

  • 40. [Chemotherapy and cardiotoxicity].
    Brestescher C; Pautier P; Farge D
    Ann Cardiol Angeiol (Paris); 1995 Oct; 44(8):443-7. PubMed ID: 8669796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.